What are the Short-Term Outcomes in Multiple Sclerosis Patients after Total Knee Arthroplasty?

J Knee Surg DOI: 10.1055/s-0038-1636836Due to the paucity of evidence, this study was conducted to evaluate: (1) unique characteristics of multiple sclerosis (MS) patients and (2) short-term clinical outcomes, of primary total knee arthroplasty (TKA) in patients with MS (MS-TKA) compared with matched non-MS patients. MS patients who underwent TKA were identified using the Nationwide Inpatient Sample (NIS) database. The study sample consisted of 10,884 patients with MS and 56,45,227 control cohort. Various patient factors were compared. To control for potential confounders, with the use of propensity scores, MS-TKA patients were matched (1:3) to non-MS-TKA patients and regression analyses were performed to compare perioperative complications, length of stay (LOS), and discharge dispositions. Patients with MS were younger, more likely to be females, on corticosteroids, and more likely to have muscle spasms and gait abnormalities. Annual frequency of TKAs in MS patients increased from 1.16/1,000 TKAs in 2002 to 2.48/1,000 TKAs in 2013 (p 
Source: Journal of Knee Surgery - Category: Orthopaedics Authors: Tags: Original Article Source Type: research

Related Links:

AbstractThe process of finding new therapeutic indications for currently used drugs, defined as ‘repurposing’, is receiving growing attention. Chloroquine and hydroxychloroquine, with an original indication to prevent or cure malaria, have been successfully used to treat several infectious (HIV, Q fever, Whipple’s disease, fungal infections), rheumatological (systemic lupus erythematosus , antiphospholipid antibody syndrome, rheumatoid arthritis, Sjögren’s syndrome), and other immunological diseases. Indeed, they have anti-inflammatory, immunomodulating, anti-infective, antithrombotic, and meta...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Conclusion: This case report highlights the patient's clinical course and includes a brief history of the systemic effects of HSE, as well as the pathophysiology, management, and differential diagnosis of post-encephalitic optic neuritis. We suggest that clinicians should routinely perform an ophthalmologic examination during the follow-up visits of such patients. PMID: 29719649 [PubMed]
Source: Journal of Ophthalmic and Vision Research - Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research
Authors: Maurelli M, Bergamaschi R, Antonini A, Fargnoli MC, Puma E, Mallucci G, Totaro R, Girolomoni G Abstract Interferon-beta (IFNβ) are effective treatments for relapsing multiple sclerosis. IFNβ treatment includes subcutaneous (sc) IFNβ-1b, intramuscular and sc IFNβ-1a, and sc pegylated IFNβ-1a (PEG-IFNβ-1a). PEG-IFNβ-1a offers the advantage of a prolonged duration of action with a less frequent administration (every 2 weeks) and a higher patient adherence. However, the use of subcutaneous interferons could be characterized by potential skin toxicity. Injection site reactions...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
ConclusionsThe present case shows that cortical lesions can occur in MS patients and might be induced by B cell‐mediated mechanisms.
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: Case Report Source Type: research
Publication date: Available online 19 February 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Jie Li, Yan Xu, Haitao Ren, Yicheng Zhu, Bin Peng, Liying Cui Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is a novel autoimmune disease. This is the first report of a case of autoimmune GFAP astrocytopathy after herpes simplex viral encephalitis (HSVE). A 35-year-old female patient presented with a combination of headache, fever, seizure and psychiatric/behavioral abnormalities. She had GFAP-IgG in both serum and cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) with gadolinium-enha...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Personalized medicine is a medical model where treatment decisions are tailored to the patient in accordance with the specific characteristics of the individual and their disease. Typically, these decisions are based on the predicted treatment response of the patient, which is based on individual disease features. At present, treatment of multiple sclerosis (MS) relapses is far from personalized medicine: most patients receive 1 or 2 courses of corticosteroids, with treatment of unresponsive relapses escalating to apheresis (either plasma exchange or immunoabsorption). Predictors of response to either corticosteroids or pl...
Source: JAMA Neurology - Category: Neurology Source Type: research
Conclusions Our results emphasize the importance of accurate screening for mood disorders in patients with MS prior to HDC initiation, and indicate that HDC should be used with caution in patients with MDQ positivity.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusion Our results support the use of PLEX in severe relapses unresponsive to corticosteroids, since it was an effective and relatively safe treatment for most of our patients.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
CONCLUSION: This pilot study, the first of its kind in France, has demonstrated the relevance and feasibility of adapting the Choosing Wisely(®) model to MS by practitioners specializing in the disorder. However, the acceptability of these recommendations by other practitioners in other specialist fields as well as their impact on everyday clinical practices now need to be studied. PMID: 29128151 [PubMed - as supplied by publisher]
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Conclusions Since corticosteroids cause a reduction in melatonin serum levels, an important hormone in sleep regulation, their prescription to MS patients should be carefully considered. Corticosteroids could be a cause of insomnia and sleep disturbance in patients receiving this type of medication.
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
More News: Corticosteroid Therapy | Databases & Libraries | Multiple Sclerosis | Orthopaedics | Study